The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) reached all time high today, Oct, 10 and still has $192.67 target or 64.00% above today’s $117.48 share price. This indicates more upside for the $10.72B company. This technical setup was reported by Barchart.com. If the $192.67 PT is reached, the company will be worth $6.86 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 78,062 shares traded hands. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 48.28% since March 7, 2016 and is uptrending. It has outperformed by 40.69% the S&P500.
Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on October, 26. They expect $0.59 earnings per share, up 9.26% or $0.05 from last year’s $0.54 per share. IDXX’s profit will be $53.84M for 49.78 P/E if the $0.59 EPS becomes a reality. After $0.80 actual earnings per share reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -26.25% negative EPS growth.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage
Out of 7 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. IDEXX Laboratories has been the topic of 13 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Monday, March 21. Stifel Nicolaus has “Buy” rating and $85 price target. CL King initiated IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Friday, April 1 with “Neutral” rating. The company was upgraded on Friday, July 24 by Feltl & Co. The firm earned “Market Perform” rating on Friday, August 28 by Raymond James. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Neutral” rating given on Thursday, September 29 by Bank of America. The firm has “Buy” rating given on Thursday, October 29 by Stifel Nicolaus. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Outperform” rating given on Wednesday, April 13 by Credit Suisse. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 13. The rating was maintained by Canaccord Genuity on Wednesday, July 20 with “Buy”. The firm has “Outperform” rating by Credit Suisse given on Thursday, February 4.
According to Zacks Investment Research, “IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.”
Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.34, from 1 in 2016Q1. The ratio is positive, as 27 funds sold all IDEXX Laboratories, Inc. shares owned while 123 reduced positions. 79 funds bought stakes while 122 increased positions. They now own 77.90 million shares or 5.94% less from 82.81 million shares in 2016Q1.
Rothschild Asset Inc owns 4,549 shares or 0.01% of their US portfolio. Headinvest Ltd Liability Corp holds 67,751 shares or 2.38% of its portfolio. Pdts Prtn Limited Liability Co holds 75,732 shares or 0.56% of its portfolio. Kbc Group Inc Nv accumulated 6,606 shares or 0.01% of the stock. Agf Investments Inc accumulated 0.01% or 13,068 shares. Parkwood Lc holds 0.77% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 49,887 shares. Hsbc Hldgs Public Limited Com holds 20,267 shares or 0.01% of its portfolio. Royal Bank Of Canada reported 207,678 shares or 0.01% of all its holdings. Marble Harbor Counsel Ltd Liability Company accumulated 63,685 shares or 1.47% of the stock. Smithfield reported 300 shares or 0.01% of all its holdings. Hemenway Tru Lc owns 10,728 shares or 0.26% of their US portfolio. California State Teachers Retirement Sys has 187,878 shares for 0.04% of their US portfolio. Livforsakringsbolaget Skandia Omsesidigt holds 0.03% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 8,200 shares. Millennium Ltd Liability Company holds 0% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 20,595 shares. Moreover, Van Eck Assoc has 0.08% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 177,709 shares.
Insider Transactions: Since May 3, 2016, the stock had 0 insider buys, and 6 insider sales for $15.03 million net activity. Shares for $542,521 were sold by END WILLIAM T. Shares for $1.11M were sold by JOHNSON BARRY C on Monday, August 15. HENDERSON REBECCA M had sold 9,924 shares worth $1.10 million on Thursday, August 25. Williams Michael J PhD sold 49,560 shares worth $5.40M. AYERS JONATHAN W sold $6.46 million worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Thursday, August 4.
More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Fool.com which released: “Why IDEXX Laboratories, Inc. Reported Higher Today” on August 02, 2016, also Fool.com with their article: “IDEXX Laboratories, Inc. Sees More Growth Ahead” published on May 02, 2016, Prnewswire.com published: “IDEXX Laboratories to Host 2016 Investor Day” on August 08, 2016. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Prnewswire.com and their article: “IDEXX Laboratories to Present at Raymond James North American Equities Conference” published on September 06, 2016 as well as Benzinga.com‘s news article titled: “Jim Cramer Gives His Opinion On Starbucks, IDEXX Laboratories And VCA” with publication date: September 27, 2016.
IDXX Company Profile
IDEXX Laboratories, Inc., incorporated in 1983, develops, makes and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Firm operates through three divisions: diagnostic and information technology services and products for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller divisions that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.